FOLLOW US

Evernorth Health Services, the health solutions arm of Cigna Corp., announced a massive $3.5 billion investment in specialty pharmacy management company Shields Health Solutions on Tuesday, signaling a high-stakes push into one of health care’s fastest-growing sectors.

The move, guided by Wachtell Lipton Rosen & Katz and Holland & Knight LLP, strengthens Evernorth’s hand in managing specialty care for patients with complex and chronic conditions, while leaving the door open for additional future investments in Shields.

Rising Demand for Specialty Medications

“Demand for specialty medications continues to grow at an accelerated pace,” said Cigna Chairman and CEO David M. Cordan, stressing that Evernorth is well positioned to support both patients and physicians.

Cordan added that the deal reflects Cigna’s broader mission: to ensure “exceptional care across health care settings — from the home to the physician’s office, clinic, and hospital.”

Who Is Shields Health Solutions?

Headquartered in Stoughton, Massachusetts, Shields works with hospitals and health systems to design and manage their own specialty pharmacies. Its reach is extensive — over 80 health systems, representing more than 1,000 hospitals and clinics in nearly every U.S. state.

Recently, Shields became a private standalone business following its acquisition by Sycamore Partners, which last week finalized a $24 billion deal to acquire Walgreens Boots Alliance Inc. That mega-transaction spun off Shields, CareCentrix, VillageMD, Walgreens Co., and The Boots Group into standalone entities.

Leaders Weigh In

Shields CEO Michael Ham hailed the partnership, saying it validated the company’s health system–focused strategy.

“Our team at Shields has been proud to deliver exceptional clinical, financial and operational outcomes for our partners and their patients,” Ham said. “Both Sycamore’s acquisition of Shields, and Evernorth’s support for the transaction, demonstrate clear validation of our specialty pharmacy model.”

For Evernorth, based in St. Louis, Missouri, the investment aligns with its existing suite of services — from direct-to-patient pharmacies and distribution to home and ambulatory infusion services.

Legal Counsel Behind the Billion-Dollar Move

The Holland & Knight team, led by partner Jeffrey Mittleman, served as regulatory counsel to Evernorth.

While full details of Wachtell’s counsel team were not immediately disclosed, a Shields representative confirmed no additional law firms advised on the deal. However, Davis Polk & Wardwell advised Sycamore Partners in its Walgreens acquisition.